357,939 Shares in PROCEPT BioRobotics Corporation $PRCT Acquired by Johnson & Johnson

Johnson & Johnson purchased a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the 2nd quarter, HoldingsChannel reports. The fund purchased 357,939 shares of the company’s stock, valued at approximately $8,082,263,000. PROCEPT BioRobotics makes up approximately 1.0% of Johnson & Johnson’s holdings, making the stock its 11th largest position.

A number of other large investors have also recently bought and sold shares of PRCT. Versant Capital Management Inc raised its stake in PROCEPT BioRobotics by 994.5% during the second quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock worth $27,000 after acquiring an additional 1,084 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after purchasing an additional 746 shares in the last quarter. Center for Financial Planning Inc. bought a new stake in shares of PROCEPT BioRobotics in the 4th quarter worth about $40,000. Cache Advisors LLC bought a new stake in shares of PROCEPT BioRobotics in the 1st quarter worth about $42,000. Finally, Essential Partners LLC increased its position in shares of PROCEPT BioRobotics by 7,071.4% during the 1st quarter. Essential Partners LLC now owns 2,008 shares of the company’s stock worth $50,000 after purchasing an additional 1,980 shares in the last quarter. 89.46% of the stock is currently owned by institutional investors.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock opened at $21.65 on Friday. The stock has a 50-day simple moving average of $21.06 and a 200 day simple moving average of $24.49. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. PROCEPT BioRobotics Corporation has a 12-month low of $16.67 and a 12-month high of $42.71. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -11.16 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The company had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. During the same quarter last year, the company earned ($0.35) EPS. The firm’s quarterly revenue was up 19.3% on a year-over-year basis. On average, research analysts anticipate that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms are soliciting investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, to seek lead-plaintiff status. The deadline is September 22, 2026. These notices are procedural and do not represent a finding that PROCEPT violated securities laws. Hagens Berman class-action notice
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or omissions regarding demand for its Aquablation-related handpieces and the gap between handpiece sales and procedures. The complaints cite repeated sales underperformance, excess customer inventory and late-quarter bulk discounts that allegedly obscured underlying demand. The allegations also challenge explanations that revenue volatility was primarily caused by temporary saline shortages. Kahn Swick & Foti class-action notice
• Negative Sentiment: Law-firm releases reference an approximately 18% share-price decline tied to the alleged inventory issues and disclosures. Continued litigation could create legal expenses, potential settlement costs and reputational damage, while the underlying inventory buildup could weigh on future unit and handpiece sales. Investors should note that the complaints contain allegations rather than proven facts. SueWallSt investor notice

Insider Buying and Selling at PROCEPT BioRobotics

In related news, CEO Larry L. Wood bought 23,900 shares of PROCEPT BioRobotics stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the transaction, the chief executive officer owned 23,900 shares of the company’s stock, valued at approximately $498,315. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold 1,000 shares of company stock valued at $28,480 over the last ninety days. Insiders own 4.00% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on PRCT. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Wells Fargo & Company lowered shares of PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective for the company. in a report on Wednesday, August 5th. Leerink Partners cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $31.00 to $29.00 in a research note on Thursday, June 11th. Jefferies Financial Group reissued a “hold” rating and issued a $20.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.00.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.